Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma.
It has been suggested that angiogenesis and angiogenic factors may be strong predictors of relapse in patients with breast carcinoma. We measured the levels of the angiogenic peptide basic fibroblast growth factor (bFGF) in 140 breast tumour cytosols using an immunoassay. There were no significant differences in bFGF levels between breast non-malignant lesions and primary carcinomas. In 124 cases with primary breast cancer, we observed an association of low bFGF levels (< 400 pg mg[-1]) with increasing tumour size (P = 0.023) and stage of disease (P = 0.002). bFGF levels did not correlate with other variables, including axillary nodes, hormone receptors, cathepsin D and the serum tumour markers CA15.3 and CEA. With a median follow-up of 44.0 months, breast cancer patients with low levels of bFGF had a significantly shorter disease-free survival (DFS) than patients with elevated bFGF (log-rank, P < 0.0001). In a multivariate analysis of DFS, only bFGF, T-stage and histological grade showed statistical significance. In a parallel evaluation of circulating bFGF, we did not observe a correlation between the serum and tissue bFGF levels in the 29 selected cases with matched determinations. Our results indicate that low bFGF levels in breast carcinoma are an independent prognostic indicator of poor prognosis and disease recurrence.
Colomer
R
R
Division of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain.
Aparicio
J
J
Montero
S
S
Guzmán
C
C
Larrodera
L
L
Cortés-Funes
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D001941:Breast Diseases / Q000097:blood / Q000175:diagnosis; D001943:Breast Neoplasms / Q000097:blood / Q000737:chemistry* / Q000175:diagnosis; D002272:Carcinoembryonic Antigen / Q000097:blood; D002402:Cathepsin D / Q000032:analysis; D003600:Cytosol / Q000737:chemistry*; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000032:analysis* / Q000097:blood; D006801:Humans; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016222:Fibroblast Growth Factor 2; D002402:Cathepsin D